Dynamic susceptibility contrast magnetic resonance imaging (DSC MRI) for Neoplasms, Brain

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
University Health Network, Toronto, Canada
Neoplasms, Brain+2 More
Dynamic susceptibility contrast magnetic resonance imaging (DSC MRI) - DiagnosticTest
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

The objectives of the study are (1) to evaluate the feasibility of using a combined spin- and gradient- echo (SAGE) sequence in dynamic susceptibility contrast magnetic resonance imaging (DSC MRI) and (2) to determine quantitative estimates of vessel density and size to differentiate between areas of radiation necrosis and tumor recurrence.

Eligible Conditions

  • Neoplasms, Brain
  • Brain

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

2 Primary · 0 Secondary · Reporting Duration: Baseline to end of study (up to 2 years)

Year 2
Measurement of perfusion parameter: cerebral blood volume (CBV)
Measurement of perfusion parameter: vessel size index (VSI)

Trial Safety

Safety Progress

1 of 3

Trial Design

1 Treatment Group

Diagnostic (DSC MRI)
1 of 1
Experimental Treatment

100 Total Participants · 1 Treatment Group

Primary Treatment: Dynamic susceptibility contrast magnetic resonance imaging (DSC MRI) · No Placebo Group · N/A

Diagnostic (DSC MRI)
DiagnosticTest
Experimental Group · 1 Intervention: Dynamic susceptibility contrast magnetic resonance imaging (DSC MRI) · Intervention Types: DiagnosticTest

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: baseline to end of study (up to 2 years)
Closest Location: University Health Network · Toronto, Canada
Photo of Toronto 1Photo of Toronto 2Photo of Toronto 3
2005First Recorded Clinical Trial
3 TrialsResearching Neoplasms, Brain
271 CompletedClinical Trials

Who is running the clinical trial?

University Health Network, TorontoLead Sponsor
1,351 Previous Clinical Trials
471,533 Total Patients Enrolled
3 Trials studying Neoplasms, Brain
68 Patients Enrolled for Neoplasms, Brain
Paula Alcaide-Leon, MDPrincipal InvestigatorUniversity Health Network, Toronto

Eligibility Criteria

Age 18+ · All Participants · 1 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.